AR039554A1 - Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios - Google Patents
Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediariosInfo
- Publication number
- AR039554A1 AR039554A1 ARP020104262A ARP020104262A AR039554A1 AR 039554 A1 AR039554 A1 AR 039554A1 AR P020104262 A ARP020104262 A AR P020104262A AR P020104262 A ARP020104262 A AR P020104262A AR 039554 A1 AR039554 A1 AR 039554A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- aryl
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos derivados de aminopirimidina y aminopiridina que tienen la fórmula (1), en la cual: uno de V ó X es N y el otro es CRa, ó ambos V y X son CRa (donde cada Ra es independientemente hidrógeno, alquilo (C1-6), cicloalquilo (C3-7) ó cicloalquil (C3-7)-alquilo (C1-6); Y es O, S ó NR; donde R es hidrógeno, CN, NO2, (alquilo C1-10), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), alquenilo (C3-10) ó alquinilo (C2-10); Z es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-6)-alquilo (C1-6), alquenilo (C2-6), alquinilo (C2-6) ó N(R2)(R3); R1 es hidrógeno, alquilo (C1-10), alquenilo (C3-10), alquinilo (C2-10), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), heteroalquilo (C1-10), heterociclilo, heterociclil-alquilo (C1-6), arilo, aril-alquilo (C1-4), aril-heteroalquilo (C1-4), heteroaril-alquilo (C1-4), heteroaril-heteroalquilo (C1-4), C(O)R11 ó alquileno (C1-6)-C(O)R11; R11 es hidrógeno, alquilo (C1-6) ó NR12R13 (donde R12 y R13 son independientemente hidrógeno, alquilo (C1-6) ó heteroalquilo (C1-6)); R2 y R3 son independientemente hidrógeno, alquilo (C1-10), alquenilo (C3-10), alquinilo (C2-10), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6) ó heteroalquilo (C1-10), ó R2 y R3 pueden combinarse para formar un anillo heterocíclico de 5-7 miembros; R4 es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), alquenilo (C2-6) ó alquinilo (C2-6); A es hidrógeno, alquilo (C1-10), alquenilo (C3-10), alquinilo (C2-10), haloalquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), heteroalquilo (C1-10), heterociclilo, heterociclil-alquilo (C1-6), cicloalquilo (C3-7) heterosustituido, arilo, aril-alquilo (C1-4), aril-heteroalquilo (C1-4), heteroarilo, heteroaril-alquilo (C1-4), heteroaril-heteroalquilo (C1-4) ó RaRbNC(=X)- donde Ra y Rb son independientemente hidrógeno, alquilo (C1-4) ó arilo y X es O ó S; B es un anillo aromático de cinco o seis miembros sustituido o no sustituido, que contiene al menos un átomo de nitrógeno, y entre 0 y 3 heteroátomos adicionales, donde los sustituyentes del anillo B se seleccionan entre halógeno, CF3, CF3O, alquilo (C1-6), amino, alquilamino (C1-6), di-alquilamino (C1-6), ciano, nitro, sulfonamido, acilo, acilamino y carboxamido; U es -NR5-, -O- ó -S-; y, R5 es hidrógeno ó alquilo (C1-6); y sales farmacéuticamente aceptables de los mismos; donde el término "heteroalquilo" se refiere a un radical alquilo (C1-6) con uno, dos o tres sustituyentes independientemente seleccionados entre ciano, -ORa, -NRbRc, y -S(O)nRd (donde n es un entero que oscila entre 0 y 2); entendiendo que el punto de unión del radical heteroalquilo es a través de un átomo de carbono del radical heteroalquilo, y Ra es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo, aril-alquilo (C1-6), alcoxicarbonilo (C1-6), ariloxicarbonilo, carboxamido, ó mono- o di-alquil (C1-6) carbamoilo, Rb es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo ó aril-alquilo (C1-6), Rc es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo, aril-alquilo (C1-6), alcoxicarbonilo (C1-6), ariloxicarbonilo, carboxamido, mono- o di-alquil (C1-6) carbamoilo, alquilsulfonilo (C1-6), -C(O)R', ó -S(O)nR' (donde n es un entero que oscila entre 0 y 2; donde R' es hidrógeno, alquilo (C1-6) ó arilo), Rd es hidrógeno (siempre y cuando n sea 0), alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo, aril-alquilo (C1-6), amino, monoalquilamino (C1-6), dialquilamino (C1-6), ó hidroxialquilo (C1-6); el término "heteroarilo" se refiere a un radical monocíclico o bicíclico monovalente que tiene entre 5 y 12 átomos en el anillo, que tiene al menos un anillo aromático que contiene uno, dos o tres heteroátomos en el anillo seleccionados entre N, O, ó S, y el resto de los átomos del anillo son C, entendiendo que el punto de unión del radical heteroarilo será en un anillo aromático, y el anillo heteroarilo está opcionalmente sustituido en forma independiente por uno a cuatro sustituyentes seleccionados entre alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), halo, nitro, ciano, hidroxi, alcoxi (C1-6), amino, acilamino, monoalquilamino (C1-6), dialquilamino (C1-6), haloalquilo (C1-6), haloalcoxi (C1-6), heteroalquilo (C1-6), -COR (donde R es hidrógeno, alquilo (C1-6), fenilo ó fenilalquilo (C1-6)), -(CR'R")n-COOR (donde n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), y R es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), fenilo ó fenilalquilo (C1-6)), ó -(CR'R")n-CONRaRb (donde n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), y Ra y Rb son, independientemente uno del otro, hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-(alquilo C1-6), fenilo ó fenilalquilo (C1-6)); el término "heterociclilo" se refiere a un radical cíclico no aromático saturado o insaturado que tiene entre 3 y 8 átomos en el anillo, donde uno o dos átomos del anillo son heteroátomos seleccionados entre O, NR (donde R es independientemente hidrógeno, alquilo (C1-6), ó cualquiera de los sustituyentes que se mencionan más adelante), ó S(O)n (donde n es un entero que oscila entre 0 y 2), y el resto de los átomos del anillo son C, donde uno o dos átomos de C pueden ser reemplazados opcionalmente por un grupo carbonilo, y el anillo de heterociclilo puede estar opcionalmente sustituido en forma independiente por uno, dos o tres sustituyentes seleccionados entre alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), aril-alquilo (C1-6), halo, nitro, ciano, cianoalquilo (C1-6), hidroxi, alcoxi (C1-6), amino, monoalquilamino (C1-6), dialquilamino (C1-6), haloalquilo (C1-6), haloalcoxi (C1-6), -(CR'R")n-COR (donde n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), R es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), fenilo, ó fenilalquilo (C1-6)), -(CR'R")n-COOR (donde n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), y R es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), fenilo ó fenilalquilo (C1-6)), -(CR'R")n-C(=Q)NRaRb (donde Q es O ó S, n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), y Ra y Rb son, independientemente uno del otro, hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquilo (C3-7)-alquilo (C1-6), heteroalquilo (C1-6), fenilo ó fenilalquilo (C1-6)), ó -(CR'R")n1-S(O)nRd (donde n1 es un entero que oscila entre 0 y 5, Rd es hidrógeno (siempre y cuando n sea 0), alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo, aril-alquilo (C1-6), amino, monoalquilamino (C1-6), dialquilamino (C1-6), ó hidroxialquilo (C1-6), y n es un entero que oscila entre 0 y 2); el término "arilo" se refiere a un radical de hidrocarburo aromático monocíclico o bicíclico monovalente que tiene entre 6 y 10 átomos en el anillo, que está opcionalmente sustituido independientemente por uno a cuatro sustituyentes seleccionados entre alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), fenilo, halo, nitro, ciano, cianoalquilo (C1-6), hidroxi, alcoxi (C1-6), amino, acilamino, monoalquilamino (C1-6), dialquilamino (C1-6), haloalquilo (C1-6), haloalcoxi (C1-6), heteroalquilo (C1-6), COR (donde R es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), fenilo ó fenilalquilo (C1-6)), -S(O)n-Rd (donde n es un entero que oscila entre 0 y 2, y cuando n es 0, Rd es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), ó cicloalquil (C3-7)-alquilo (C1-6), y cuando n es 1 ó 2, Rd es alquilo (C1-6), cicloalquilo (C3-7), cicloalquilo (C3-7)-alquilo (C1-6), amino, acilamino, monoalquilamino (C1-6), ó dialquilamino (C1-6)), -NS(O)2Rf (donde Rf es alquilo (C1-6) ó arilo), -NHCORe (donde Re es amino, alquilamino (C1-6), dialquilamino (C1-6) ó alcoxi (C1-4)), -(CR'R")n-COOR (donde n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), y R es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquilo (C3-7)-alquilo (C1-6), fenilo ó fenilalquilo (C1-6)), -(CR'R")nS(O)n-Rd (donde n es un entero que oscila entre 0 y 2, y cuando n es 0, Rd es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), ó cicloalquil (C3-7)-alquilo (C1-6), y cuando n es 1 ó 2, Rd es alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), amino, acilamino, monoalquilamino (C1-6), ó dialquilamino (C1-6)), -(CR'R")n-CONRaRb (donde n es un entero que oscila entre 0 y 5, R' y R" son independientemente hidrógeno ó alquilo (C1-6), y Ra y Rb son, independientemente uno del otro, hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), fenilalcoxi (C1-4) ó fenilalquilo (C1-6)) ó cualesquiera dos átomos de carbono adyacentes están sustituidos por -O(CH2)nO- (donde n es 1 ó 2); el término "acilo" se refiere al grupo -C(O)R', donde R' es hidrógeno, alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo y aril-alquilo (C1-6); el término "cicloalquilo heterosustituido" se refiere a un grupo cicloalquilo (C3-7) en donde uno, dos o tres átomos de hidrógeno se reemplazan por sustituyentes seleccionados independientemente entre el grupo que comprende ciano, cianometilo, hidroxi, hidroximetilo, alcoxi (C1-6), amino, acilamino, monoalquilamino (C1-6), dialquilamino (C1-6), -SOnR (donde n es un entero que oscila entre 0 y 2 y cuando n es 0, R es hidrógeno ó alquilo (C1-6) y cuando n es 1 ó 2, R es alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), arilo, aril-alquilo (C1-6), heteroarilo, amino, acilamino, monoalquilamino (C1-6), dialquilamino (C1-6), ó hidroxialquilo (C1-6)) ó -NHSO2R d
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33831201P | 2001-11-07 | 2001-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039554A1 true AR039554A1 (es) | 2005-02-23 |
Family
ID=23324288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104262A AR039554A1 (es) | 2001-11-07 | 2002-11-07 | Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios |
Country Status (12)
Country | Link |
---|---|
US (2) | US6846828B2 (es) |
EP (1) | EP1444223A1 (es) |
JP (1) | JP2005511608A (es) |
KR (1) | KR20050042062A (es) |
CN (1) | CN1582284A (es) |
AR (1) | AR039554A1 (es) |
BR (1) | BR0213899A (es) |
CA (1) | CA2465711A1 (es) |
MX (1) | MXPA04004166A (es) |
PL (1) | PL370480A1 (es) |
RU (1) | RU2308455C2 (es) |
WO (1) | WO2003040131A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
EP1490354A1 (en) * | 2002-03-09 | 2004-12-29 | Astrazeneca AB | 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
CN100441569C (zh) * | 2003-02-24 | 2008-12-10 | 横滨橡胶株式会社 | 化合物和使用了该化合物的组合物 |
GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
US20070225291A1 (en) * | 2003-10-14 | 2007-09-27 | Pfizer Inc. | Substituted Pyrazinone Compounds for the Treatment of Inflammation |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
CN102796081B (zh) * | 2004-08-28 | 2015-04-22 | 阿斯利康(瑞典)有限公司 | 作为趋化因子受体调节剂的嘧啶磺酰胺衍生物 |
EP1828183A1 (en) * | 2004-12-17 | 2007-09-05 | AstraZeneca AB | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
GB0514017D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
EP1912974A1 (en) * | 2005-07-30 | 2008-04-23 | AstraZeneca AB | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
BRPI0616722A2 (pt) * | 2005-09-30 | 2012-12-25 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas |
AR058277A1 (es) * | 2005-12-09 | 2008-01-30 | Solvay Pharm Gmbh | N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
US20110117121A1 (en) * | 2006-10-27 | 2011-05-19 | James Dao | Compositions for treatment and inhibition of pain |
IN2012DN05169A (es) * | 2009-12-02 | 2015-10-23 | Acceleron Pharma Inc | |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
CN109776525B (zh) | 2013-04-19 | 2022-01-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019099307A1 (en) * | 2017-11-17 | 2019-05-23 | Hepagene Therapeutics, Inc. | Urea derivatives as inhibitors of ask1 |
BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
KR102441327B1 (ko) * | 2018-05-18 | 2022-09-07 | 주식회사유한양행 | 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법 |
CN109336800B (zh) * | 2018-09-17 | 2022-11-29 | 江西中医药大学 | 一种dhnb缩苯基氨基硫脲化合物及其制备方法和用途 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN115919864B (zh) * | 2022-12-02 | 2024-09-03 | 中南大学湘雅三医院 | 唑嘧啶胺类化合物在用于制备治疗ibd药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2095240A (en) * | 1981-03-05 | 1982-09-29 | Fujisawa Pharmaceutical Co | Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
EP0457717B1 (de) | 1990-05-16 | 1995-10-25 | Sulzer Chemtech AG | Verfahren zur gerichteten fraktionierten Kristallisation |
EP0457727A1 (de) * | 1990-05-17 | 1991-11-21 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
IL106786A (en) * | 1992-09-10 | 1997-02-18 | Basf Ag | Substituted pyridine derivatives and fungicidal compositions containing them |
WO2001056553A2 (en) * | 2000-02-02 | 2001-08-09 | Axxima Pharmaceuticals Ag | Pharmaceutically active aromatic guanylhydrazones |
CA2427284A1 (en) | 2000-10-26 | 2002-05-30 | Tularik Inc. | Antiinflammation agents |
-
2002
- 2002-10-31 CA CA002465711A patent/CA2465711A1/en not_active Abandoned
- 2002-10-31 JP JP2003542177A patent/JP2005511608A/ja active Pending
- 2002-10-31 MX MXPA04004166A patent/MXPA04004166A/es not_active Application Discontinuation
- 2002-10-31 PL PL02370480A patent/PL370480A1/xx not_active Application Discontinuation
- 2002-10-31 BR BR0213899-9A patent/BR0213899A/pt not_active IP Right Cessation
- 2002-10-31 CN CNA02822194XA patent/CN1582284A/zh active Pending
- 2002-10-31 EP EP02785344A patent/EP1444223A1/en not_active Withdrawn
- 2002-10-31 KR KR1020047006970A patent/KR20050042062A/ko not_active Application Discontinuation
- 2002-10-31 RU RU2004117545/04A patent/RU2308455C2/ru not_active IP Right Cessation
- 2002-10-31 WO PCT/EP2002/012164 patent/WO2003040131A1/en active Application Filing
- 2002-11-06 US US10/288,968 patent/US6846828B2/en not_active Expired - Fee Related
- 2002-11-07 AR ARP020104262A patent/AR039554A1/es not_active Application Discontinuation
-
2004
- 2004-10-18 US US10/967,430 patent/US7157580B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1444223A1 (en) | 2004-08-11 |
RU2308455C2 (ru) | 2007-10-20 |
US20050107403A1 (en) | 2005-05-19 |
WO2003040131A1 (en) | 2003-05-15 |
US7157580B2 (en) | 2007-01-02 |
US6846828B2 (en) | 2005-01-25 |
CN1582284A (zh) | 2005-02-16 |
BR0213899A (pt) | 2004-08-31 |
KR20050042062A (ko) | 2005-05-04 |
JP2005511608A (ja) | 2005-04-28 |
MXPA04004166A (es) | 2004-07-08 |
PL370480A1 (en) | 2005-05-30 |
RU2004117545A (ru) | 2005-05-27 |
US20030144303A1 (en) | 2003-07-31 |
CA2465711A1 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039554A1 (es) | Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios | |
AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
AR052559A1 (es) | Derivados de pirazol para inhibir cdk's y gsk's | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
AR040080A1 (es) | Inhibidores del virus de la hepatitis c | |
AR082681A1 (es) | Inhibidores del virus de la hepatitis c | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
PE20090042A1 (es) | Analogos de ciclopamina | |
AR080264A1 (es) | Inhibidores ns5a de vhc | |
AR069740A1 (es) | Compuestos nucleosidos antivirales | |
AR071268A1 (es) | Derivados de bencilfenilciclohexano, metodos de uso y una composicion farmaceutica | |
CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
RU2015121431A (ru) | Замещенные производные индол-5-ола и их терапевтическое применение | |
AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
AR076259A2 (es) | Derivados de 3,5-dietil-1h-pirazol-4-il-oxi nitrilos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones por hiv | |
AR041734A1 (es) | Compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos | |
AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
BRPI0415433A (pt) | derivados de n-[fenil (alquilpiperidin-2-il)metil] benzamida, seu preparo e sua aplicação em terapêutica | |
AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR050266A1 (es) | Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa | |
AR063151A1 (es) | Inhibidores de metaloproteasas de matriz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |